182 related articles for article (PubMed ID: 36908323)
1. Cancerous inhibitor of protein phosphatase 2A enhances chemoresistance of gastric cancer cells to oxaliplatin.
Zhao YX; Ma LB; Yang Z; Wang F; Wang HY; Dang JY
World J Gastrointest Oncol; 2023 Feb; 15(2):286-302. PubMed ID: 36908323
[TBL] [Abstract][Full Text] [Related]
2. Increase in CIP2A expression is associated with cisplatin chemoresistance in gastric cancer.
Ji J; Zhen W; Si Y; Ma W; Zheng L; Li C; Zhang Y; Qin S; Zhang T; Liu P; Zheng X; Liu Y
Cancer Biomark; 2018 Feb; 21(2):307-316. PubMed ID: 29103022
[TBL] [Abstract][Full Text] [Related]
3. [Ethoxysanguinarine directly targets CIP2A to inhibit proliferation and induce autophagy of SGC7901/DDP cells].
Wan F; Tan M; Xiang YC; Liu XW; Peng P; Liu Y
Zhongguo Zhong Yao Za Zhi; 2022 Nov; 47(21):5890-5899. PubMed ID: 36472008
[TBL] [Abstract][Full Text] [Related]
4. Tamoxifen induces apoptosis through cancerous inhibitor of protein phosphatase 2A-dependent phospho-Akt inactivation in estrogen receptor-negative human breast cancer cells.
Liu CY; Hung MH; Wang DS; Chu PY; Su JC; Teng TH; Huang CT; Chao TT; Wang CY; Shiau CW; Tseng LM; Chen KF
Breast Cancer Res; 2014 Sep; 16(5):431. PubMed ID: 25228280
[TBL] [Abstract][Full Text] [Related]
5. Cancerous inhibitor of protein phosphatase 2A regulates cisplatin resistance in ovarian cancer.
Li W; Zhang H; Yang L; Wang Y
Oncol Lett; 2019 Jan; 17(1):1211-1216. PubMed ID: 30655886
[TBL] [Abstract][Full Text] [Related]
6. SP1-induced lncRNA DUBR promotes stemness and oxaliplatin resistance of hepatocellular carcinoma via E2F1-CIP2A feedback.
Liu S; Bu X; Kan A; Luo L; Xu Y; Chen H; Lin X; Lai Z; Wen D; Huang L; Shi M
Cancer Lett; 2022 Mar; 528():16-30. PubMed ID: 34958891
[TBL] [Abstract][Full Text] [Related]
7. Effect of CIP2A and its mechanism of action in the malignant biological behavior of colorectal cancer.
Chen W; Liang JL; Zhou K; Zeng QL; Ye JW; Huang MJ
Cell Commun Signal; 2020 Apr; 18(1):67. PubMed ID: 32321509
[TBL] [Abstract][Full Text] [Related]
8. Knockdown of cancerous inhibitor of protein phosphatase 2A may sensitize NSCLC cells to cisplatin.
Wei L; Qu W; Sun J; Wang X; Lv L; Xie L; Song X
Cancer Gene Ther; 2014 May; 21(5):194-9. PubMed ID: 24874844
[TBL] [Abstract][Full Text] [Related]
9. Expression of CIP2A in renal cell carcinomas correlates with tumour invasion, metastasis and patients' survival.
Ren J; Li W; Yan L; Jiao W; Tian S; Li D; Tang Y; Gu G; Liu H; Xu Z
Br J Cancer; 2011 Dec; 105(12):1905-11. PubMed ID: 22075943
[TBL] [Abstract][Full Text] [Related]
10. Knockdown of cancerous inhibitor of protein phosphatase 2A may sensitize metastatic castration-resistant prostate cancer cells to cabazitaxel chemotherapy.
Huang J; Jia J; Tong Q; Liu J; Qiu J; Sun R; Yao L; Yang C
Tumour Biol; 2015 Mar; 36(3):1589-94. PubMed ID: 25377160
[TBL] [Abstract][Full Text] [Related]
11. CIP2A is a predictor of poor prognosis in colon cancer.
Teng HW; Yang SH; Lin JK; Chen WS; Lin TC; Jiang JK; Yen CC; Li AF; Chen PC; Lan YT; Lin CC; Hsu YN; Wang HW; Chen KF
J Gastrointest Surg; 2012 May; 16(5):1037-47. PubMed ID: 22328001
[TBL] [Abstract][Full Text] [Related]
12. CIP2A is a target of bortezomib in human triple negative breast cancer cells.
Tseng LM; Liu CY; Chang KC; Chu PY; Shiau CW; Chen KF
Breast Cancer Res; 2012 Apr; 14(2):R68. PubMed ID: 22537901
[TBL] [Abstract][Full Text] [Related]
13. Cucurbitacin B induces autophagy and apoptosis by suppressing CIP2A/PP2A/mTORC1 signaling axis in human cisplatin resistant gastric cancer cells.
Liu X; Duan C; Ji J; Zhang T; Yuan X; Zhang Y; Ma W; Yang J; Yang L; Jiang Z; Yu H; Liu Y
Oncol Rep; 2017 Jul; 38(1):271-278. PubMed ID: 28534965
[TBL] [Abstract][Full Text] [Related]
14. CIP2A is overexpressed in gastric cancer and its depletion leads to impaired clonogenicity, senescence, or differentiation of tumor cells.
Li W; Ge Z; Liu C; Liu Z; Björkholm M; Jia J; Xu D
Clin Cancer Res; 2008 Jun; 14(12):3722-8. PubMed ID: 18559589
[TBL] [Abstract][Full Text] [Related]
15. Celastrol impairs tumor growth by modulating the CIP2A-GSK3β-MCL-1 axis in gastric cancer cells.
Wu J; Ye F; Xu T
Aging (Albany NY); 2023 Jul; 15(14):6894-6904. PubMed ID: 37470692
[TBL] [Abstract][Full Text] [Related]
16. MYC-dependent regulation and prognostic role of CIP2A in gastric cancer.
Khanna A; Böckelman C; Hemmes A; Junttila MR; Wiksten JP; Lundin M; Junnila S; Murphy DJ; Evan GI; Haglund C; Westermarck J; Ristimäki A
J Natl Cancer Inst; 2009 Jun; 101(11):793-805. PubMed ID: 19470954
[TBL] [Abstract][Full Text] [Related]
17. Arctigenin inhibits triple-negative breast cancers by targeting CIP2A to reactivate protein phosphatase 2A.
Huang Q; Qin S; Yuan X; Zhang L; Ji J; Liu X; Ma W; Zhang Y; Liu P; Sun Z; Zhang J; Liu Y
Oncol Rep; 2017 Jul; 38(1):598-606. PubMed ID: 28560452
[TBL] [Abstract][Full Text] [Related]
18. siRNA-Mediated Silencing of CIP2A Enhances Docetaxel Activity Against PC-3 Prostate Cancer Cells.
Razi Soofiyani S; Mohammad Hoseini A; Mohammadi A; Khaze Shahgoli V; Baradaran B; Hejazi MS
Adv Pharm Bull; 2017 Dec; 7(4):637-643. PubMed ID: 29399554
[No Abstract] [Full Text] [Related]
19. CIP2A down regulation enhances the sensitivity of pancreatic cancer cells to gemcitabine.
Xu P; Yao J; He J; Zhao L; Wang X; Li Z; Qian J
Oncotarget; 2016 Mar; 7(12):14831-40. PubMed ID: 26894380
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of CIP2A determines erlotinib-induced apoptosis in hepatocellular carcinoma.
Yu HC; Chen HJ; Chang YL; Liu CY; Shiau CW; Cheng AL; Chen KF
Biochem Pharmacol; 2013 Feb; 85(3):356-66. PubMed ID: 23178652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
